<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285204</url>
  </required_header>
  <id_info>
    <org_study_id>ELA-AF-OCT-2014-01</org_study_id>
    <nct_id>NCT03285204</nct_id>
  </id_info>
  <brief_title>Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia</brief_title>
  <official_title>Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jose Luis Urcelay Segura</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Gregorio Mara침on</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to obtain an early biomarker of amyotrophic lateral sclerosis and
      Friedreich's Ataxia which allows to diagnose the disease in an initial stage and to follow up
      the patient with optic coherence tomography, a fast, non-invasive and comfortable method
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be asked about their data and their general medical history, and will be
      underwent on one hand, a complete neurological examination including the degree of
      neurological impairment quantified according to the functional rating scale of ALS (ALSFRS-r)
      or Scale for the assessment and rating of ataxia (SARA); On the other hand, they will have a
      complete ophthalmological examination too, including the patient's graduation, pupillary and
      ocular motility examination, biomicroscopy, Goldman tonometry and fundus exam. Patients will
      be performed too a conventional automated Humprey perimetry, color test (Farnsworth-Munsell
      28 Hue Color Vision Test) and finally an optical coherence tomography (OCT) in order to see
      possible anatomical alterations in both macula and optic nerve. The follow-up of these
      explorations will be repeated in all cases at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>early biomarker of amyotrophic lateral sclerosis and Friedreich's Ataxia</measure>
    <time_frame>change from baseline to 6 month</time_frame>
    <description>macular, ganglion cell layer and retinal nerve fiber layer thickness measure</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Friedreich Ataxia patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Amyotrophic lateral sclerosis patients Friedreich's ataxia patients Healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years.

          -  Best corrected visual acuity more than 0.4 (20/50 Snellen = 0.4 logMAR = 65 ETDRS
             letters).

          -  Refractive defect less than 5 diopters of spherical equivalent and / or cylinder less
             than 2 diopters.

          -  Transparent optical media: Opacity of crystalline &lt;1 according to Lens Opacities
             Classification System (LOCS) III.

          -  Open anterior chamber angle assessed by gonioscopy with Goldmann lens (grade&gt; III).

          -  Availability and collaboration to carry out the tests of the exploratory protocol.

          -  Acceptance of informed consent.

        Exclusion Criteria:

          -  Previous intraocular surgeries of less than 6 months of evolution. Patients with
             refractive surgery using the LASIK or LASEK technique will not be excluded.

          -  Physical or mental difficulties to perform reliable and reproducible perimeters.

          -  Pathology and / or ocular malformations, angular or optic nerve anomalies.

          -  Any retinopathy or maculopathy.

          -  Intraocular pressure (IOP)&gt; 21 mmHg.

          -  Signal-to-noise ratio in OCT less than 5/10.

          -  Failure to meet any inclusion criteria.

          -  Mental retardation or any other limitation in obtaining informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Urcelay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HGU Gregorio Mara침칩n</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pilar Rojas, MD</last_name>
    <phone>+34616042758</phone>
    <email>pilar.rojas.lozano@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pilar Rojas Lozano</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Rojas Lozano</last_name>
      <phone>+34616042758</phone>
      <email>pilar.rojas.lozano@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>April 7, 2018</last_update_submitted>
  <last_update_submitted_qc>April 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Mara침on</investigator_affiliation>
    <investigator_full_name>Jose Luis Urcelay Segura</investigator_full_name>
    <investigator_title>Head Of ophthalmology</investigator_title>
  </responsible_party>
  <keyword>optical coherence tomography</keyword>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

